LLY's explosive growth from Mounjaro and Zepbound outpaces MRK's Keytruda-led gains, despite valuation concerns.

Eli Lilly's stock took a noticeable dip following a guidance update from rival Novo Nordisk. Investors reacted sharply as ...

According to TipRanks.com, Wright is a 5-star analyst with an average return of 12.3% and a 61.9% success rate. Wright covers the Healthcare sector, focusing on stocks such as Phibro Animal Health, ...

Results for the second quarter were a bit better than expected. Non-GAAP earnings were $2.13 per share, better than the $2.02 ...

LLY's oncology sales are expected to have climbed in Q2, led by Verzenio growth, despite pressure from older cancer drugs.

Novo Nordisk A/S ADR (NVO-N) NYSE Add to Watchlist Create Alerts 126.99 USD +0.53 +0.42% Real-Time Last Update 04/03/24 Last Sale Cboe BZX Real-Time Volume 3,609,254 Summary Charts Profile ...

Few things can jolt a pharmaceutical company's shares like positive results from highly anticipated clinical trials. Even so, ...

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

Jefferies analysts initiated Eli Lilly & Co. (NYSE: LLY) with a Hold rating and $290 price target and Merck & Company Inc (NYSE: MRK) with a Buy rating and $125 price target in separate notes to ...

An obesity drug from Hengrui Pharma and Kailera Therapeutics succeeded in a late-stage trial in China, while Anne Wojcicki's ...

On Monday, Eli Lilly and Co. released data from its study of 1,700 patients showing its Alzheimer's drug, donanemab, also slows progression of the disease. (Eisai/The Associated Press) ...